Literature DB >> 31298316

MiR-1271 inhibits cell proliferation and metastasis by targeting LDHA in endometrial cancer.

Y Tian1, Y-Y Chen, A-L Han.   

Abstract

OBJECTIVE: Endometrial cancer (EC) is one of the most frequent malignant with high incidence worldwide. The poor prognosis of EC is mainly due to the lack of efficient treatment and diagnosis. The biological role of microRNA-1271 (miR-1271) in EC is still unknown. In the current research, we mainly aimed to figure out the role of miR-1271 in EC progression. PATIENTS AND METHODS: MiR-1271 expression in EC was evaluated by quantitative Real-time polymerase chain reaction (qRT-PCR) assay. Cell counting kit-8 (CCK-8) assay and colony formation assay were employed to examine cell proliferation ability. Transwell assay and Matrigel assay were conducted to detect cell migration and invasion. Bioinformatics analysis and dual-luciferase reporter gene assay were employed to predict and verify the target genes of miR-1271. The protein level of lactate dehydrogenase A (LDHA) was assessed by Western blotting with normalization to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
RESULTS: MiR-1271 was downregulated in EC through qRT-PCR determination. CCK-8 assay and colony formation assay indicated that over-expression of miR-1271 suppressed cell proliferation in EC. Through the transwell assay and Matrigel assay, the data indicated that miR-1271 suppressed cell migration and invasion. By bioinformatics analysis and dual-luciferase reporter gene assay, LDHA was verified to be a direct downstream target of miR-1271. In the rescue assay, it was proved that miR-1271 inhibited cell proliferation and metastasis by regulating LDHA in EC.
CONCLUSIONS: We showed that miR-1271 functioned as a tumor suppressor in EC by targeting LDHA, which may bring a novel insight for developing novel biomarkers and treatment strategies in EC.

Entities:  

Year:  2019        PMID: 31298316     DOI: 10.26355/eurrev_201907_18300

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  Resibufogenin suppresses tumor growth and Warburg effect through regulating miR-143-3p/HK2 axis in breast cancer.

Authors:  Ying Guo; Fei Liang; Fuli Zhao; Jian Zhao
Journal:  Mol Cell Biochem       Date:  2020-01-31       Impact factor: 3.842

2.  LncRNA TTN‑AS1 promotes endometrial cancer by sponging miR‑376a‑3p.

Authors:  Longde Shen; Yinyin Wu; Ailu Li; Lichun Li; Longyuan Shen; Qiuxia Jiang; Qiuxia Li; Zhifen Wu; Liji Yu; Xiaohong Zhang
Journal:  Oncol Rep       Date:  2020-07-15       Impact factor: 3.906

Review 3.  MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy.

Authors:  Milad Ashrafizadeh; Hui Li Ang; Ebrahim Rahmani Moghadam; Shima Mohammadi; Vahideh Zarrin; Kiavash Hushmandi; Saeed Samarghandian; Ali Zarrabi; Masoud Najafi; Reza Mohammadinejad; Alan Prem Kumar
Journal:  Biomolecules       Date:  2020-07-12

4.  MicroRNA‑1271‑5p alleviates the malignant development of hepatitis B virus‑mediated liver cancer via binding to AQP5.

Authors:  Zhigang Li; Lin Ma; Lingling Di; Xutao Lin
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

5.  Circular RNA intraflagellar transport 80 facilitates endometrial cancer progression through modulating miR-545-3p/FAM98A signaling.

Authors:  Na Wang; Yunfeng Guo; Liqin Song; Tong Tong; Xiaomei Fan
Journal:  J Gynecol Oncol       Date:  2021-10-25       Impact factor: 4.401

6.  Upregulation of lncRNA ZFAS1 promotes lung adenocarcinoma progression by sponging miR-1271-5p and upregulating FRS2.

Authors:  Gang Fan; Jin Jiao; Feng Shen; Fulu Chu
Journal:  Thorac Cancer       Date:  2020-06-08       Impact factor: 3.500

Review 7.  Small Non-Coding-RNA in Gynecological Malignancies.

Authors:  Shailendra Kumar Dhar Dwivedi; Geeta Rao; Anindya Dey; Priyabrata Mukherjee; Jonathan D Wren; Resham Bhattacharya
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.